Abstract
AbstractPharmacogenomics (PGx) is the study of genetic influences on an individual’s response to medications. Improvements in the quality and quantity of PGx research over the past two decades have enabled the establishment of commercial markets for PGx tests. Nevertheless, PGx testing has yet to be adopted as a routine practice in clinical care. Accordingly, policy regulating the commercialization and reimbursement of PGx testing is in its infancy. Several papers have been published on the topic of challenges, or ‘barriers’ to clinical adoption of this healthcare innovation. However, many do not include recent evidence from randomized controlled trials, economic utility studies, and qualitative assessments of stakeholder opinions. The present paper revisits the most cited barriers to adoption of PGx testing: evidence for clinical utility, evidence for economic effectiveness, and stakeholder awareness. We consider these barriers in the context of reviewing PGx literature published over the past two decades and emphasize data from commercial PGx testing companies, since they have published the largest datasets. We conclude with a discussion of existing limitations to PGx testing and recommendations for progress.
Funder
Tanenbaum Centre for Pharmacogenetics (Centre for Addiction and Mental Health); Government of Ontario Ministry of Research and Innovation
Publisher
Springer Science and Business Media LLC
Subject
Biological Psychiatry,Cellular and Molecular Neuroscience,Psychiatry and Mental health
Reference72 articles.
1. Samer CF, Lorenzini KI, Rollason V, Daali Y, Desmeules JA. Applications of CYP450 testing in the clinical setting. Mol Diagnosis Ther. 2013;17:165–84.
2. Gaedigk A. Complexities of CYP2D6 gene analysis and interpretation. Int Rev Psychiatry. 2013;25:534–53.
3. Nassan M, Nicholson WT, Elliott MA, Rohrer Vitek CR, Black JL, Frye MA. Pharmacokinetic pharmacogenetic prescribing guidelines for antidepressants. Mayo Clin Proc. 2016;91:897–907.
4. Pratt VM, Scott, SA. Clopidogrel Therapy and CYP2C19Genotype. Ch. 2.17. In: Pirmohamed M, Esquivel B, Kane MS, Kattman BL, Malheiro AJ, editors. Medical Genetics Summaries. 2nd ed. Bethesda, Maryland: National Center for Biotechnology Information (NCBI); 2021.
5. Gross T, Daniel J. Overview of pharmacogenomic testing in clinical practice. Mental Health Clin. 2018. https://doi.org/10.9740/mhc.2018.09.235.
Cited by
28 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献